What is Amplia Therapeutics Limited?
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 56.93M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.